Fig. 6From: RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinomaA combined risk score for IO/TKI therapy prognosis and benefit. (A) Variable importance of predictive parameters enrolled in the random forest risk model. (B) PFS of subgroups defined by risk score and therapeutic regimens. P value, Kaplan-Meier analysis and log-rank testBack to article page